Search results for "ASTHMA"

showing 10 items of 860 documents

Dose-Related Effect of Beclomethasone Dipropionate on Airway Responsiveness in Asthma

1990

The effects of twice daily inhaled beclomethasone dipropionate (BDP) at two dose levels (500 and 1,000 micrograms daily) on the airway responsiveness to inhaled histamine was evaluated by a randomized, single-blind, cross-over study in 10 patients with stable asthma. The 12-week study began with a 3-week run-in period of baseline treatment, which was continued unchanged throughout the study, and the two treatment periods were separated by a 3-week placebo period. Patients attended the laboratory every 3 weeks for spirometry and histamine inhalation tests to determine the provocative concentration of histamine causing a 20% fall in forced expiratory volume in 1 s (PC20 of FEV1). There was a …

AdultMalePulmonary and Respiratory MedicineSpirometryAllergymedicine.drug_classPlaceboRandom Allocationchemistry.chemical_compoundForced Expiratory VolumemedicineHumansLungAsthmaDose-Response Relationship DrugInhalationmedicine.diagnostic_testbusiness.industryAirway ResistanceBeclomethasoneBeclometasone dipropionateMiddle Agedrespiratory systemmedicine.diseaseAsthmachemistryAnesthesiaCorticosteroidFemalebusinessHistamineHistaminemedicine.drugRespiration
researchProduct

The Lack of the Bronchoprotective and Not the Bronchodilatory Ability of Deep Inspiration Is Associated with Airway Hyperresponsiveness

2001

In healthy subjects, deep inspiration (DI) acts both as a bronchodilator and a bronchoprotector. The latter is impaired in asthmatics. We have now evaluated whether the lack of bronchoprotection is related to bronchial hyperresponsiveness (BHR), and whether the bronchodilatory effect is also lost in asthmatics. Ten healthy subjects (PC20 > 75 mg/ml), 12 asthmatics with moderate to severe BHR (PC20 < 1 mg/ml), 14 asthmatics with mild to borderline BHR (1 < PC20 < 25 mg/ml), and 10 rhinitics with mild to borderline BHR (1 < PC20 < 25 mg/ml) underwent single-dose methacholine provocations inducing at least 20% reduction in FEV1 after 20 min of DI inhibition. To measure the bronchodilatory effe…

AdultMalePulmonary and Respiratory MedicineSpirometryRhinitis Allergic Perennialmedicine.drug_classBronchoconstrictionSettore MED/10 - Malattie Dell'Apparato RespiratorioCritical Care and Intensive Care MedicineBronchial Provocation TestsFEV1/FVC ratioReference ValuesRisk FactorsForced Expiratory VolumeBronchodilatormedicineHumansReference ValueMethacholine ChlorideAsthmaBronchusmedicine.diagnostic_testbusiness.industryMiddle Agedrespiratory systemmedicine.diseaseAsthmarespiratory tract diseasesBronchial Provocation TestBronchodilatationmedicine.anatomical_structureInhalationBronchial hyperresponsivenessAnesthesiaFemaleMethacholineBronchial HyperreactivitybusinessHumancirculatory and respiratory physiologymedicine.drugAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Effect of Salmeterol on Seasonal Changes in Airway Responsiveness and Exhaled Nitric Oxide in Pollen-Sensitive Asthmatic Subjects

2002

Objective Using a model of natural allergen exposure, we examined the effect of regular treatment with salmeterol on allergen-induced changes in airway responsiveness and exhaled nitric oxide (ENO). Design Double-blind, randomized, parallel-group study. Setting Specialist allergy unit in a university hospital. Patients Asthmatic patients sensitized to pollen allergens were randomly allocated to monotherapy with salmeterol (n = 14) or placebo (n = 13). Interventions Salmeterol, 25 μg, and placebo inhalers, two puffs bid, for 6 weeks. Measurements Spirometry, the level of a provocative concentration of a substance (methacholine) causing a 20% fall in FEV 1 (PC 20 ), the PC 20 level for adenos…

AdultMalePulmonary and Respiratory MedicineSpirometrymedicine.medical_specialtyAdolescentmedicine.drug_classNitric OxideCritical Care and Intensive Care MedicinePlaceboDouble-Blind MethodForced Expiratory VolumeInternal medicineBronchodilatorAdministration InhalationmedicineHumansAlbuterolExpirationSalmeterol XinafoateAsthmamedicine.diagnostic_testbusiness.industryAirway ResistanceRhinitis Allergic SeasonalMiddle Agedrespiratory systemmedicine.diseaseAdenosine MonophosphateAsthmarespiratory tract diseasesEndocrinologyBreath TestsExhaled nitric oxideFemaleMethacholineSeasonsSalmeterolCardiology and Cardiovascular Medicinebusinessmedicine.drugChest
researchProduct

18-yr cumulative incidence of respiratory/allergic symptoms/diseases and risk factors in the Pisa epidemiological study

2019

Abstract Background Few population-based studies on the effects of environmental exposure variation exist. Aim Assessing respiratory symptom/disease incidence related to risk factor exposure changes. Methods A longitudinal general population sample from two surveys (PISA2:1991–1993; PISA3:2009–2011; no. = 970), aged ≥20 years at baseline, completed a questionnaire on respiratory symptoms/diseases, risk factor exposure and performed spirometry. 18-year follow-up cumulative incidence of respiratory symptoms/diseases and longitudinal changes (persistence, incidence, remittance) in risk factor exposure were computed. Results Cumulative incidence values were: 3.2% (corresponding to a 1.8‰/year i…

AdultMalePulmonary and Respiratory MedicineSpirometrymedicine.medical_specialtyTime FactorsAllergyPopulationYoung Adult03 medical and health sciences0302 clinical medicineRisk FactorsSurveys and QuestionnairesInternal medicineWheezeTobaccomedicineCOPDHumansCumulative incidence030212 general & internal medicineeducationEnvironmental and occupational Health and EpidemiologyAgedAsthmaCOPDeducation.field_of_studymedicine.diagnostic_testbusiness.industryIncidence (epidemiology)SmokingEnvironmental ExposureEnvironmental exposureMiddle AgedRespiration Disordersmedicine.diseaseAsthmarespiratory tract diseases030228 respiratory systemAllergy; Asthma; COPD; Environmental & occupational health and epidemiology; TobaccoFemalemedicine.symptombusinessEnvironmental & occupational health and epidemiologyRespiratory Medicine
researchProduct

The Effect of Spirometry on Bronchial and Alveolar Nitric Oxide in Subjects with Asthma

2013

The effect of spirometric maneuvers on exhaled nitric oxide (NO) at the constant flow rate of 50 ml/s (FE(NO)) has been studied with equivocal results. Furthermore, the effects of spirometry on bronchial NO flux (J'aw(NO)) and alveolar NO (CA(NO)), two measurements increasingly being used in clinical and research protocols, are unknown. The aim of this study was to evaluate the effect of spirometry on FE(NO), J'aw(NO), and CA(NO) in adults with asthma.Forty-four adults with asthma were studied. To assess the impact of exhaled NO measurement itself on exhaled NO values, FE(NO), J'aw(NO), and CA(NO) were obtained twice, at baseline and after a resting period of 10 min. Then spirometry (with o…

AdultMalePulmonary and Respiratory MedicineSpirometrymedicine.medical_specialtymedicine.drug_classBronchiNitric OxideNitric oxidechemistry.chemical_compoundForced Expiratory VolumeInternal medicineBronchodilatormedicineHumansImmunology and AllergyAsthmamedicine.diagnostic_testConstant flowbusiness.industryrespiratory systemmedicine.diseaseAsthmarespiratory tract diseasesPulmonary AlveolichemistrySpirometryPediatrics Perinatology and Child HealthExhaled nitric oxideCardiologyFemalebusinessJournal of Asthma
researchProduct

Airway Responsiveness to Histamine in Patients Refractory to Repeated Exercise

1988

To investigate the mechanisms contributing to refractoriness in exercise-induced asthma (EIA), airway responsiveness to histamine was studied in eight asthmatic patients. Patients were included in the study on the basis of their refractory response to multiple exercise challenges. Incremental challenges with inhaled histamine were performed at rest and 40 minutes after single and paired exercise tests. The geometric mean histamine concentration required to produce a 20 percent fall in FEV1 (PC20) for the challenge after paired exercise test (4.34 mg/ml) was significantly higher (p greater than 0.001) than those for the challenges after a single exercise (1.05 mg/ml) and for the challenge at…

AdultMalePulmonary and Respiratory MedicineTime FactorsRefractory periodPhysical ExertionCritical Care and Intensive Care MedicineBronchial Provocation Testschemistry.chemical_compoundRefractoryForced Expiratory VolumeHumansMedicineAsthmatic patientIn patientAsthmabusiness.industryRespiratory diseasemedicine.diseaseAsthmaAsthma Exercise-InducedchemistryAnesthesiaExercise TestFemaleCardiology and Cardiovascular MedicinebusinessAirway responsivenessHistamineHistamineChest
researchProduct

Effects of Inhaled Fenoterol on the Circadian Rhythm of Expiratory Flow in Allergic Bronchial Asthma

1983

Metered-dose aerosol treatment with fenoterol for three consecutive days, in eight patients suffering from allergic asthma, caused the disappearance of FEV1 and MEF50 circadian rhythm. We attribute such behavior to the suppression of the bronchomotor tone induced by fenoterol. The administration on different days of a single dose of fenoterol aerosol in another group of eight patients pointed out the variability of the effects of the drug at different hours of the day. We believe the results obtained are important for a better dosage and time distribution of the therapy with beta2 agonists.

AdultMalePulmonary and Respiratory MedicineTime distributionMaximal Midexpiratory Flow RateCritical Care and Intensive Care MedicinemedicineHumansCircadian rhythmFenoterolFenoterolAsthmaAerosolsbusiness.industryAllergic asthmaForced Expiratory Flow RatesMaximal midexpiratory flow raterespiratory systemmedicine.diseaseAsthmaCircadian RhythmForced Expiratory Flow RatesB2 receptorEthanolaminesAnesthesiaFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugChest
researchProduct

Monitoring free serum IgE in severe asthma patients treated with omalizumab

2012

SummaryBackgroundBenefit of treatment with the monoclonal anti-IgE-antibody omalizumab in severe IgE-dependent asthma requires a significant reduction of serum free IgE concentrations. It is unclear if monitoring free serum IgE is clinically meaningful once omalizumab treatment is initiated.MethodsFree IgE and omalizumab serum concentrations were quantified in 22 patients with severe asthma (68% female, 47 ± 11 yrs, mean (±SD) pre-bronchodilator FEV1 62 ± 13%, baseline mean (±SEM) free serum IgE 652 ± 136 ng/ml) treated with omalizumab for 4 months using a Recovery-ELISA.ResultsOmalizumab treatment reduced free serum IgE prior to the second omalizumab injection by 73%, after 16 weeks by 81%…

AdultMalePulmonary and Respiratory MedicineTreatment responsemedicine.medical_specialtySevere asthmaInjections SubcutaneousEnzyme-Linked Immunosorbent AssayOmalizumabOmalizumabTarget rangeAntibodies Monoclonal HumanizedImmunoglobulin EGastroenterologyAnti-asthmatic AgentSerum igeYoung AdultInternal medicinemedicineHumansIn patientAnti-Asthmatic AgentsAgedAsthmabiologybusiness.industryRespiratory diseaseMiddle AgedImmunoglobulin Emedicine.diseaseAsthmaAntibodies Anti-IdiotypicClinical trialTreatment OutcomeFree serum IgEMonoclonalImmunologybiology.proteinFemaleAntibodybusinessmedicine.drugRespiratory Medicine
researchProduct

The prevalence of sleep impairments and predictors of sleep quality among patients with asthma

2020

Background: Sleep is a significant dimension of daily life. However, only a few studies have examined the sleep quality of asthmatics in a real-world clinical settings. Objective: This study is aimed to estimate the prevalence of sleep impairments among asthmatic patients and examine the relationship between sleep quality, asthma control, rhinitis symptoms, and sociodemographic characteristics. Methods: The present study adopted the observational cross-sectional research design that has been designed by the Italian Respiratory Society and used valid assessments to measure the study variables. Results: Data from 1150 asthmatic patients (mean age 51.01 years ± 16.03) were subjected to analysi…

AdultMalePulmonary and Respiratory Medicineasthma; quality of life; reflux; rhinitis; sleep; sleepiness;Settore MED/09 - Medicina InternaCross-sectional studySettore MED/10 - Malattie Dell'Apparato RespiratoriosleepinessQuality of life (healthcare)rhinitisSleep Initiation and Maintenance DisordersPrevalencemedicineHumansImmunology and AllergysleepAgedAsthmaAsthma quality of life reflux rhinitis sleep sleepinessSleep Apnea ObstructiveSleep qualitybusiness.industryMiddle Agedmedicine.diseaseSleep in non-human animalsAsthma; quality of life; reflux; rhinitis; sleep; sleepinessAsthmarhinitiasthma sleep rhinitis sleepiness reflux quality of lifeCross-Sectional StudiesSocioeconomic Factorsquality of lifePediatrics Perinatology and Child HealthGastroesophageal RefluxFemaleSettore MED/26 - NeurologiarefluxbusinessClinical psychology
researchProduct

Characteristics and Prognostic Value of Morning Dipping of Peak Expiratory Flow Rate in Stable Asthmatic Subjects

1985

Characteristics and prognostic relevance of morning dip of peak expiratory flow rate (PEFR) were evaluated in stable asthmatic subjects. Among 246 outpatients monitored four times daily for two weeks, 38 (group A) showed a significant difference between morning reading of PEFR and each of the others; they were compared to 38 randomly selected patients (group B) not showing morning dip in PEFR. Less frequent seasonal course, extrinsic pathogenesis, and sensitization to mites characterized group A; starting airflow limitation was more severe in those with morning dip, but no significant difference between mean PEFR measured throughout two weeks was found. At 6 to 12 weeks, morning dip was not…

AdultMalePulmonary and Respiratory Medicinebusiness.industrySignificant differenceSeasonal coursePeak Expiratory Flow RateForced Expiratory Flow RatesMiddle AgedPrognosisCritical Care and Intensive Care Medicinemedicine.diseaseAsthmaCircadian RhythmPeak expiratory flow rate measurementForced Expiratory VolumeAnesthesiamedicineHumansFemaleRisk factorCardiology and Cardiovascular MedicinebusinessAsthmaMorningChest
researchProduct